skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Zoledronic acid in the management of metastatic bone disease

Review

(2595) Views  (548) Full article downloads

Authors: Thomas J Polascik, Vladimir Mouraviev

Published Date March 2008 Volume 2008:4(1) Pages 261 - 268
DOI: http://dx.doi.org/10.2147/TCRM.S2707

Thomas J Polascik, Vladimir Mouraviev

Duke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC, USA

Abstract: Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying osteoporosis and/or cancer treatment induced bone loss. The clinical consequences of metastatic disease involving the skeleton are widespread. This review focuses on the efficacy, pharmacology, and safety when using intravenous biphosphonate such a zoledronic acid for cancer bone metastases. Zoledronic acid is the gold standard for the medical management of metastatic bone disease. The indications for treatment include prevention of skeletal relevant events (SRE), osteoporotic complications, and palliation of bone pain, among others. Zoledronic acid is the only bisphosphonate effective in decreasing SREs associated with bone metastases from advanced renal cell carcinoma and prostate cancer. Regarding prostate cancer, zoledronic acid effectively prevents both bone loss in patients with locally advanced disease receiving androgen deprivation therapy and SREs in men with hormone-refractory or hormonesensitive metastatic disease. Zoledronic acid has an acceptable safety profile and tolerability, and has been effective at significantly decreasing the incidence, delaying the onset, and reducing the overall risk of experiencing an SRE compared to placebo. It is the only bisphosphonate currently approved for the prevention and treatment of skeletal complications in patients with bone metastases due to all solid tumors.

Keywords: zoledronic acid, metastatic bone disease, osteoporosis, skeletal relevant events, advanced prostate cancer






 

Other articles by Dr Thomas Polascik



Readers of this article also read:

The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
Novel mechanisms of central nervous system damage in HIV infection
Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells
Erratum